



Manufacturer's Information **Test No. 21-5002: Drug Analysis**

Each sample pack consisted of two items. Item 1 contained a single blue tablet containing approximately 2 mg of flunitrazepam and Firmapress powder. Item 2 contained a single white tablet containing Firmapress powder. Flunitrazepam is a Schedule IV controlled substance in the United States.

SAMPLE PREPARATION-

The flunitrazepam in Item 1 was a pure powder that was combined with blue Firmapress powder consisting of high-quality excipients. These two powders were mixed thoroughly to ensure homogeneity. Item 2 consisted solely of white Firmapress powder.

ITEM 1 (PREPARATION): Using a tablet press, tablets were created using the prepared mixture of flunitrazepam and blue Firmapress powder. The average mass of each tablet was approximately 270 mg. One tablet was deposited into a glassine bag which was folded and secured with a label. The folded glassine bag was placed into a small zip top bag, which was heat sealed and then placed into a pre-labeled envelope.

ITEM 2 (PREPARATION): Using a tablet press, tablets were created using white Firmapress powder. The average mass of each tablet was approximately 250 mg. One tablet was deposited into a glassine bag which was folded and secured with a label. The folded glassine bag was placed into a small zip top bag, which was heat sealed and then placed into a pre-labeled envelope.

SAMPLE PACK ASSEMBLY: One of each of the Item 1 and Item 2 envelopes was placed into a larger pre-labeled sample pack envelope.

VERIFICATION: The above substances were identified by predistribution laboratories, who used the following combined list of techniques: color tests and GC/MS.

Note: During the distribution of this test, multiple participants discovered that one or both items arrived as a crushed tablet or in powder form.

The information presented here details how test samples were prepared as well as any design specifications. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample(s). Final interpretation of the results should be deferred until the summary report is available.